[ARRY] Array BioPharma Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 8.8 Change: 0.19 (2.21%)
Ext. hours: Change: 0 (0%)

chart ARRY

Refresh chart

Strongest Trends Summary For ARRY

ARRY is in the medium-term up 60% above S&P in 1 year. In the long-term up 452% in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. Its proprietary clinical programs in Phase II clinical trial include ARRY-797, a p38 program for Lamin A/C-related dilated cardiomyopathy; and ARRY-502, a CRTh2 antagonist to treat Th2-driven allergic disease. The company?s proprietary programs also comprise Filanesib, a kinesin spindle protein inhibitor for multiple myeloma; and ARRY-614, a p38/Tie2 dual inhibitor for myelodysplastic syndromes. Its partnered clinical programs include various drug candidates, including Binimetinib, an MEK inhibitor for cancer; Selumetinib, an MEK inhibitor for cancer; ASLAN001/ARRY-543, an HER2/EGFR inhibitor for gastric cancer; Ipatasertib/GDC-0068, an AKT inhibitor for cancer; VTX-2337, a toll-like receptor for cancer; and Danoprevir, a Hepatitis C virus protease inhibitor. The company?s partnered clinical program

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-0.71 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 9.82% Sales Growth - Q/Q-75.48% P/E-10.59
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-2.94% ROE-12.23% ROI-3.87%
Current Ratio4.38 Quick Ratio Long Term Debt/Equity0.71 Debt Ratio0.9
Gross Margin-7.14% Operating Margin-5.45% Net Profit Margin-13.45% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities38.85 M Cash From Investing Activities12.56 M Cash From Operating Activities21.47 M Gross Profit-5.54 M
Net Profit58.31 M Operating Profit54.47 M Total Assets208.44 M Total Current Assets196.59 M
Total Current Liabilities44.92 M Total Debt107.98 M Total Liabilities158.29 M Total Revenue6.6 M
Technical Data
High 52 week24.85 Low 52 week12.92 Last close22.39 Last change0.18%
RSI26.37 Average true range0.73 Beta1.32 Volume2.74 M
Simple moving average 20 days-5.82% Simple moving average 50 days-3.78% Simple moving average 200 days27.59%
Performance Data
Performance Week-6.2% Performance Month-8.43% Performance Quart28.31% Performance Half45.39%
Performance Year46.44% Performance Year-to-date57.12% Volatility daily2.34% Volatility weekly5.23%
Volatility monthly10.71% Volatility yearly37.11% Relative Volume178.42% Average Volume3.3 M
New High0.46% New Low


2019-06-13 08:01:40 | See what the IHS Markit Score report has to say about Array Biopharma Inc.

2019-06-11 08:02:07 | See what the IHS Markit Score report has to say about Array Biopharma Inc.

2019-06-10 09:39:39 | Here is What Hedge Funds Think About Array Biopharma Inc ARRY

2019-06-10 08:02:39 | See what the IHS Markit Score report has to say about Array Biopharma Inc.

2019-06-08 08:09:37 | See what the IHS Markit Score report has to say about Array Biopharma Inc.

2019-06-06 09:31:01 | Why Is Array BioPharma ARRY Up 27.1% Since Last Earnings Report?

2019-06-04 16:05:00 | Array BioPharma to Present at the Goldman Sachs 40?? Annual Global Healthcare Conference

2019-06-04 09:21:00 | 3 Cancer Stocks Given a Lift by Amgen

2019-06-04 08:04:30 | See what the IHS Markit Score report has to say about Array Biopharma Inc.

2019-06-03 12:18:00 | Here's Why Mirati Therapeutics Is Jumping Today

2019-05-30 10:34:00 | 2 Ultra-High-Growth Biotech Stocks to Buy Now

2019-05-29 16:05:00 | Array BioPharma to Present at the Jefferies 2019 Global Healthcare Conference

2019-05-29 11:55:00 | Array BioPharma Announces Presentation of Updated Overall Survival from the Phase 3 COLUMBUS Trial of BRAFTOVI + MEKTOVI in advanced BRAF-mutant Melanoma at 2019 ASCO Annual Meeting

2019-05-23 08:54:12 | Array BioPharma Inc. ARRY Shares March Higher, Can It Continue?

2019-05-22 17:13:09 | Array BioPharma Gains on Colorectal Cancer Study Success

2019-05-22 08:39:48 | 3 Big Stock Charts for Wednesday: Oracle, Lamb Weston Holdings and TJX Companies

2019-05-22 07:34:00 | The Daily Biotech Pulse: Tocagen Tumbles, OncoSec Offering, Novartis Asthma Combo Drug Study

2019-05-21 16:30:00 | Why Dycom Industries, Array BioPharma, and Circor International Jumped Today

2019-05-21 13:55:27 | Array Biopharma Tests Highs on Clinical Trial Results

2019-05-21 12:42:00 | Here's Why Array BioPharma Is Surging Today

2019-05-21 08:00:01 | Array BioPharma's colorectal cancer combo treatment meets main goals

2019-05-21 08:00:00 | Array BioPharma Announces BRAFTOVI + MEKTOVI + Cetuximab Meet Primary Endpoints of ORR and OS in Phase 3 BEACON CRC Trial Interim Analysis for the Treatment of BRAFV600E-mutant Metastatic Colorectal Cancer

2019-05-18 15:18:23 | Bulls And Bears Of The Week: Apple, Chevron, FedEx, Uber And More

2019-05-16 14:51:44 | Why Array BioPharma Shares Fell Thursday

2019-05-10 09:00:01 | All You Need to Know About Array BioPharma ARRY Rating Upgrade to Buy

2019-05-09 16:05:00 | Array BioPharma to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference

2019-05-08 09:56:01 | Array BioPharma ARRY Q3 Earnings and Sales Beat Estimates

2019-05-07 21:43:08 | Edited Transcript of ARRY earnings conference call or presentation 7-May-19 1:00pm GMT

2019-05-07 16:18:30 | Boulder biotech firm beats expectations despite year-over-year losses on income, revenue

2019-05-07 15:23:50 | Array Biopharma Inc ARRY Q3 2019 Earnings Call Transcript

2019-05-07 09:15:01 | Array BioPharma ARRY Reports Q3 Loss, Tops Revenue Estimates

2019-05-07 08:05:59 | Array BioPharma: Fiscal 3Q Earnings Snapshot

2019-05-07 08:04:07 | See what the IHS Markit Score report has to say about Array Biopharma Inc.

2019-05-07 08:00:00 | Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2019

2019-04-30 16:05:00 | Array BioPharma to Report Financial Results for the Third Quarter of Fiscal 2019 on May 7, 2019

2019-04-30 08:02:41 | See what the IHS Markit Score report has to say about Array Biopharma Inc.

2019-04-26 15:37:46 | The Array BioPharma NASDAQ:ARRY Share Price Is Up 610% And Shareholders Are Delighted

2019-04-26 11:25:34 | Did Hedge Funds Drop The Ball On Array Biopharma Inc ARRY ?

2019-03-27 16:16:45 | Analysts Raised Target Price for Array Biopharma in March

2019-03-18 08:00:00 | BRAFTOVI® encorafenib in Combination with MEKTOVI® binimetinib and ERBITUX® cetuximab or panitumumab Recommended by the National Comprehensive Cancer Network® NCCN Guidelines as a Treatment Option for Patients with Advanced BRAF-mutant Colorectal Cancer

2019-03-07 12:18:08 | How Financially Strong Is Array BioPharma Inc. NASDAQ:ARRY?

2019-03-06 07:57:00 | Why Array BioPharma Stock Soared 22.9% in February

2019-03-05 16:05:00 | Array BioPharma to Present at the 39th Annual Cowen Health Care Conference

2019-03-05 14:40:34 | 3 Small Caps Posting Big Gains

2019-03-04 08:35:00 | Recent Analysis Shows Array BioPharma, Nabors Industries, Brinker International, Piedmont Office Realty Trust, Och-Ziff Capital Management Group, and Franklin Street Properties Market Influences — Renewed Outlook, Key Drivers of Growth

2019-02-26 13:34:22 | 5 Stocks Seeing Insider Selling Right Now

2019-02-21 16:05:00 | Array BioPharma to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference

2019-02-14 14:02:07 | Zoetis ZTS Beats on Q4 Earnings & Sales, Shares Up

2019-02-08 08:03:13 | See what the IHS Markit Score report has to say about Array Biopharma Inc.

2019-02-07 06:34:11 | Will Array BioPharma Continue to Surge Higher?